[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multicenter-prospective-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multicenter-prospective-study":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604450","pbc-long-term-outcomes-study-100604450",false,"NCT07149675","PBC Long-term Outcomes Study","A Multi-center Prospective-retrospective Study of the Clinical Characteristics, Biochemical Response, and Long-term Outcomes in Patients With Primary Biliary Cholangitis","Inclusion Criteria:\n\n* Diagnosis consistent with PBC.\n* Willingness to participate, with informed consent obtained from the patient or legal representative (if the patient is deceased or cognitively impaired), and ability to adhere to follow-up.\n\nExclusion Criteria:\n\n* Co-existing chronic hepatitis B or C, drug-induced liver injury, autoimmune hepatitis, primary sclerosing cholangitis, or hereditary\u002Fmetabolic liver diseases.\n* Co-existingMalignancy or severe cardiac, pulmonary, renal, cerebral, or hematologic disorders expected to substantially shorten life expectancy.\n* Incomplete baseline medical records or laboratory data.","ALL",{"count":18,"type":19},4000,"ESTIMATED","3 Years","OBSERVATIONAL","Primary biliary cholangitis (PBC) is an autoimmune liver disease predominantly affecting middle-aged women. While historically it was deemed rare, advancements in specific auto-antibody tests have led to increased recognition of PBC. The long-term survival of PBC patients in China is not yet fully understood. Several studies have investigated the prognosis of PBC in China. While these studies provide valuable insights into the disease characteristics and prognostic factors of PBC in China, they are all single-center studies with limitations. They lack consideration of the impact of symptoms, varying disease stages, and second-line treatments on prognosis. Therefore, there is a pressing need for multicenter and large-scale studies to further elucidate the characteristics and long-term survival of PBC patients in China.\n\nBiochemical response to ursodeoxycholic acid (UDCA) is an independent factor associated with long-term survival. Unfortunately, approximately 30-40% of PBC patients demonstrate insufficient biochemical response to UDCA. In our cohort, we reported a higher nonresponse rate, with about 44% according to the Paris I criteria. These patients remain at risk for disease progression to advanced stages and may benefit from additional second-line drug therapies. With significant advancements in the development of new drugs for PBC, a comprehensive understanding of patients with suboptimal responses to UDCA-including long-term prognosis, the distribution of different disease stages, and the prevalence of pruritus-will provide a basis for individualized treatment strategies.\n\nAdditionally, fatigue and pruritus are prevalent symptoms for PBC patients and fluctuates independently of disease activity or stage, which significantly diminishing health-related quality of life. However, the incidence and impact of fatigue and pruritus on long-term outcomes for PBC patients in China need further clarification.\n\nTherefore, we would like to conduct this multicenter study to estimate the prevalence of PBC in China and to evaluate the symptomatic burden, treatment, and long-term outcomes among PBC patients in China.",[24,25,26,27],"Primary Biliary Cholangitis (PBC)","Long-term Outcomes","Prognosis","Multicenter Prospective Study",[29,30,31,32,33],"Primary biliary cholangitis","long-term outcomes","prognosis","multicenter","Symptoms","RECRUITING","2025-08-24",{"date":37,"type":38},"2025-09-02","ACTUAL",{"date":40,"type":38},"2025-05-18",{"date":42,"type":19},"2029-12-31",{"name":44,"class":45},"Beijing Friendship Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100578762","prevalence-of-post-anesthesia-care-unit-complications-and-associated-factors-100578762","NCT06815510","Prevalence of Post Anesthesia Care Unit Complications and Associated Factors","Multicentral Observational Prospective Study on Prevalence of Post Anesthesia Care Unit Complications and Associated Factors","Inclusion Criteria:\n\n* All patients admitted to the Post-Anesthesia Care Units (PACUs) following surgery under general, regional, or monitored anesthesia\n\nExclusion Criteria:\n\n* Patients who are taken directly to the ICU, ward, discharged, or transferred immediately after surgery.\n* Patients who do not provide informed consent for enrollment in the study.","18 Years",{"count":56,"type":19},1532,"The post-anesthesia care unit (PACU) is a crucial component of the surgical process, providing patients with vital support and monitoring as they recover from anesthesia. Despite advancements in perioperative anesthesia, PACU complications are still common. PACU organization and setup in low-income country like Ethiopia is poor. Previous research's done in some neighbor African countries presumed to have comparable to sociodemographic and economical profile shows varied degree of incidence and prevalence of PACU complication and associated factors. The main objective of this study is to determine the prevalence of PACU complications and its associated factors.\n\nAn institutional based prospective cohort study will be conducted in the PACUs of the three selected tertiary care hospitals in Ethiopia from Februery 15, 2025 to June 30, 2025. These data will be compared with those obtained in a tertiary hospital in Spain.",[59,60,61,62,27],"Postoperative Care","Complications of Surgical Procedures or Medical Care","Inpatients","Ethiopia",[64,65],"postoperative complications","postanesthesia care unit","2025-02-26",{"date":68,"type":38},"2025-02-28",{"date":70,"type":38},"2025-02-24",{"date":72,"type":19},"2025-07-01",{"name":74,"class":45},"Ángel Becerra-Bolaños, MD PhD",4]